Alcon Inc. - 500 Beiträge pro Seite

[Coinage]

hallo,

hat jemand historische fundamentale daten von alcon inc.(wkn 542019) ?

gem. börse-online ( heft 23 ) dürfte es sich bei alcon um einen der knapp gewordenen wachstumswerte handeln.

zur info:

nestle brachte alcon im märz diesen jahres zum preis von 33 us-dollar an die börse. alcon soll mit einer operativen marge von ca. 21 % arbeiten und sei in den letzten 10 jahren 10 % p.a. gewachsen. alcon sei marktführer in der augenchirugie (marktanteil von 43 %)und soll im bereich der augenheilmittel sowie pflegeprodukte für kontaktlinsen pp., gut positioniert sein. marktkap. ca. 11,6 mrd us-dollar.

wenn ihr auswertbare historische daten hier einstellen könnt, ggf. auch weitere positive/ negative aussichten, meinungen, kommentare, wäre ich euch sehr dankbar.

gruss c.

[Coinage]

trotz der beachtlichen resonanz bringe ich zur info einige artikel ein:


Alcon Overview

We develop, manufacture and market ophthalmic pharmaceuticals, ophthalmic surgical equipment and devices, contact lens care products and other consumer eye care products that treat diseases and conditions of the eye. With the exception of eye-glasses and contact lenses, we operate in all areas of ophthalmology. Our broad range of products represents the strongest portfolio in the ophthalmic industry, and we have leading market share positions across most major product categories.

Alcon History

Alcon was founded in 1945, when two pharmacists, Robert Alexander and William Con ner, opened a small pharmacy in Fort Worth, Texas, combining the first syllables of their last names to call it ALCON. After strong growth, our leadership in the ophthalmic market was well established and in 1978 we were wholly acquired off the New York Stock Exchange by Nestlé, S.A. (the world’s largest food company). We re-entered the NYSE forty times larger than we left it when we completed a partial IPO of our shares on March 21, 2002. Our shares trade under the ticker symbol ACL.

Incorporated in Hunenberg, Switzerland, with our principal U. S. operations in Fort Worth, Texas, we have operations in 75 countries. Our products are sold in more than 180 countries and we have a highly skilled workforce of more than 11,000 employees worldwide. Competing in a large and growing $11 billion market place, our global sales represent 17% of the ophthalmic pharmaceutical market, 43% of the ophthalmic surgical market and 18% of the ophthalmic consumer market, making Alcon the largest, most profitable and purest ophthalmic company worldwide.

With sales in 2001 of $2.75 billion dollars, our focus is clear: to build on our position as the largest and most innovative eye care company in the world to create value for our shareholders. At Alcon, we are dedicated to fostering new innovation for eye care, as well as converting new discoveries into commercially viable products. We will invest well in excess of $1 billion in research and development over the next four years, more than any other ophthalmology company. With a robust pipeline and an aggressive program for new product development, we expect new products and registrations will drive our growth well into the future.

[Coinage]

noch eine aktuelle info:

Alcon Laboratories, Inc. CFO to Retire June 30, Replacement Named Effective July 1

HUNENBERG, Switzerland, Jun 10, 2002 /PRNewswire-FirstCall via COMTEX/ -- Alcon, Inc. (NYSE: ACL) announced today that Charles E. Miller, Sr., senior vice president and chief financial officer of its subsidiary Alcon Laboratories, Inc., has elected to retire effective June 30, 2002 after 22 years of service. Mr. Miller advised the company that he had made his decision in order to devote more time to his real estate investments in Florida, which also will allow him to spend more time with his family. Jacqualyn A. Fouse, who most recently served as chief financial officer of the Swissair Group, was named as his replacement and will join Alcon again effective July 1, 2002.

"Charles has had a tremendous career with Alcon over the past 22 years," said Tim Sear, Alcon Inc.`s president and chief executive officer. "I have worked closely with Charles for most of his career and will miss his counsel and friendship. I am personally grateful for his contributions to our recent initial public offering, and while I am sorry to see him leave now, I understand and respect his decision. We wish him great success in his future endeavors."

Mr. Miller has served as CFO of Alcon Laboratories, Inc. since 1997. He held a number of positions in Finance prior to his promotion, including corporate treasurer and vice president/controller of the International Division. "My time at Alcon has been truly rewarding," Mr. Miller said. "I`ve thoroughly enjoyed helping the company evolve from a relatively small privately-held concern into a large public company that is the leader of the growing global eye care market. Sales when I joined were only about $150 million and now they are approaching the $3 billion mark."

Ms. Fouse first joined Alcon in 1986 and served in a variety of financial positions throughout the organization. In 1993 she moved to Switzerland to join Nestle as assistant controller for the Pharma-Cosmetics group, responsible for coordinating all of Alcon`s financial and operating relationships with Nestle. After spending three years in this department, Ms. Fouse was promoted to deputy treasurer, then to group treasurer of Nestle. During her tenure in Treasury, she had extensive interactions with the major global commercial and investment banks. She left Nestle to become chief financial officer of the Swissair Group in June 2001, where her responsibilities were broadened to include all the financial and accounting functions of that Swiss company.

"I am very excited to return to my roots at Alcon," Ms. Fouse said. "Alcon`s management team is the best in the industry and I have the highest respect for what they have done over the years. Furthermore, Charles has put in place a deep and talented financial team, many of whom have been in senior positions with the company for more than 15 years."

Tim Sear noted, "We are delighted that Jackie has decided to once again join the Alcon team. Her depth of knowledge of our company and breadth of experience with the financial markets gained during her service with large public companies make her well suited to step into her new role."

Alcon, Inc. is the world`s leading eye care company. Alcon, which has been dedicated to the ophthalmic industry for more than 50 years, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contact lens solutions and other vision care products that treat diseases, disorders and other conditions of the eye.

Caution Concerning Forward-Looking Statements. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by our forward-looking statements. These statements reflect the views of our management as of the date of this press release with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward- looking statements. Factors that might cause future results to differ include, but are not limited to, the following: approval of drug applications by the FDA, competition from other drugs, challenges inherent in new product manufacturing and marketing, developments in legal cases and government regulation and legislation. You should read this press release with the understanding that our actual future results may be materially different from what we expect. Except to the extent required under the federal securities laws and the rules and regulations promulgated by the Securities and Exchange Commission, we undertake no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.